Loading...
Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance
Jove, M. Spencer, Jade A. Clench, M. Twelves, C.
Jove, M.
Spencer, Jade A.
Clench, M.
Twelves, C.
Publication Date
2019-09
End of Embargo
Supervisor
Rights
Crown Copyright © 2019 Published by Elsevier B.V. All rights reserved. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2019-06-13
Institution
Department
Awarded
Embargo end date
Collections
Abstract
Failure of systemic cancer treatment can be, at least in part, due to the drug not being delivered to the tumour at sufficiently high concentration and/or sufficiently homogeneous distribution; this is termed as “pharmacokinetic drug resistance”. To understand whether a drug is being adequately delivered to the tumour, “precision pharmacology” techniques are needed. Mass spectrometry imaging (MSI) is a relatively new and complex technique that allows imaging of drug distribution within tissues. In this review we address the applicability of MSI to the study of cancer drug distribution from the bench to the bedside. We address: (i) the role of MSI in pre-clinical studies to characterize anti-cancer drug distribution within the body and the tumour, (ii) the application of MSI in pre-clinical studies to define optimal drug dose or schedule, combinations or new drug delivery systems, and finally (iii) the emerging role of MSI in clinical research.
Version
Accepted manuscript
Citation
Jove M, Spencer J, Clench M et al (2019) Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. Critical Reviews in Oncology/Hematology. 141: 153-162.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article